FTRE — Fortrea Holdings Inc. stock price, charts and financials

QT88Fortrea Holdings Inc.

Fortrea Holdings Inc. (NASDAQ: FTRE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
18.94
-0.23-1.20%
OverviewShort InterestFilings
FTREQT88Fortrea Holdings Inc.·NASDAQ
18.94-1.20%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IOVA+6.14%$4.32MRVI-2.28%$6.42SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E-EPS (ttm)-4.93Insider Own3.31%Shs Outstand95.10MPerf Week-1.79%
Market Cap1.82BForward P/E18.03EPS next Y1.06Insider Trans-0.76%Shs Float94.20MPerf Month9.04%
Enterprise Value1.73BPEG-EPS next Q-Inst Own-Short Float10.89%Perf Quarter66.70%
Income-85.87MP/S0.68EPS this Y116.82%Inst Trans-Short Ratio7.18Perf Half Y12.43%
Sales2.68BP/B3.45EPS next Y28.19%ROA-3.14%Short Interest10.26MPerf YTD11.13%
Book/sh-P/C9.91EPS next 5Y26.15%ROE-15.53%52W High21.13 -10.38%Perf Year209.19%
Cash/sh-P/FCF12.11EPS past 3/5Y-ROIC0.62%52W Low5.21 263.76%Perf 3Y-42.08%
Dividend Est.-EV/EBITDA21.36Sales past 3/5Y-1.36% 1.08%Gross Margin17.11%Volatility7.03% 5.14%Perf 5Y-
Dividend TTM-EV/Sales0.65EPS Y/Y TTM-34.33%Oper. Margin0.41%ATR (14)1.10Perf 10Y-
Dividend Ex-Date-Quick Ratio0.96Sales Y/Y TTM0.48%Profit Margin-3.18%RSI (14)58.50Recom2.67
Dividend Gr. 3/5Y-Current Ratio0.96EPS Q/Q-SMA203.91%Beta2.37Target Price20.00
Payout0.00%Debt/Eq0.15Sales Q/Q-2.15%SMA5013.21%Rel Volume1.29Prev Close19.17
Employees14,300LT Debt/Eq1.95EarningsNov 04SMA20040.55%Avg Volume1.48MPrice18.94
IPO DateJun 20, 2023Option/ShortYes / YesEPS/Sales Surpr.161.50% 1.27%Net Debt/EBITDA-1.09Volume1,913,679Change-1.20%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-30-26ReiteratedDeutsche BankHold$18 → $20
Jul-30-26ReiteratedRobert W. Baird$21 → $23
Jul-30-26ReiteratedBarclaysEqual Weight$18 → $22
Jul-13-26ReiteratedMizuhoNeutral$15 → $16
Jun-24-26ReiteratedBarclaysEqual Weight$16 → $18
May-07-26ReiteratedDeutsche BankHold$11 → $14
May-06-26ReiteratedTruist FinancialBuy$16 → $19
May-06-26ReiteratedRobert W. Baird$15 → $20
May-06-26ReiteratedBarclaysEqual Weight$11 → $16
Apr-14-26ReiteratedBarclaysEqual Weight$15 → $11
Latest News
Jul-31-26
Jul-31-2604:11PM
Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $22Benzinga
01:01PM
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Knowzacks.com
12:40PM
FTRE vs. ARGX: Which Stock Is the Better Value Option?zacks.com
11:02AM
Best Momentum Stock to Buy for July 31stzacks.com
09:55AM
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentumzacks.com
Jul-29-26
Jul-29-2605:13PM
Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcriptseekingalpha.com
11:08AM
Fortrea Q2 Earnings Call Highlightsmarketbeat.com
09:26AM
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimateszacks.com
06:30AM
Fortrea Reports Second Quarter 2026 Resultsglobenewswire.com
Jul-24-26
Jul-24-2605:00AM
Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS GrowthSeekingAlpha
Jul-23-26
Jul-23-2607:00AM
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firmbusinesswire.com
Jul-13-26
Jul-13-2609:00AM
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Callglobenewswire.com
08:14AM
Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $16Benzinga
Jul-09-26
Jul-09-2602:06PM
Stocks Look Shaky, But This Sector is Booming (Biotech)zacks.com
Jul-07-26
Jul-07-2612:41PM
FTRE or ARGX: Which Is the Better Value Stock Right Now?zacks.com
Company

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue2,6772,7232,6962,8432,8373,0582,580
Cost of Goods Sold Incl. D&A2,2192,2982,1622,2522,1132,4532,091
Gross Profit458426534591724604489
Selling, General and Administrative Excl. Other413456561448416303268
Research and Development
0000000
Other Operating Expense340135111121187535
Operating Income11-31-16232187114-314
Interest Expense849112470000
Unusual Expense
———————
Non-Operating Income (Expense)-5-861117022-18
Net Income Before Taxes-78-983-275-30187136-332
Income Taxes73-31413827
Consolidated Net Income-85-986-328-2518698-359
Net Income From Continuing Operations-85-986-271-3214698-359
Net Income-85-986-328-2518698-359
EPS (Recurring)-0.93-10.81-3.67-0.042.111.11-4.06
EPS (Basic, Before Extraordinaries)-0.93-10.81-3.67-0.042.111.11-4.06
EPS (Diluted)-0.93-10.81-3.67-0.042.111.11-4.06
EBITDA81-814-64137281303222
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio0.670.580.621.09———
Gross Margin17.1115.6419.8120.7925.5219.7518.95
Operating Margin0.41-1.14-6.011.136.593.73-12.17
Net Margin-3.18-36.21-12.17-0.886.563.20-13.91
Shares Outstanding94919089888888
Market Capitalization1,7801,5701,6783,106———
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$23.20$17.79$12.38$6.97$1.56● Close Price0.00K101.79K203.57K305.36K407.15KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Smith David RossDirectorJul 20 '26Option Exercise0.006,598036,715Jul 27
Smith David RossDirectorJun 10 '26Option Exercise0.0038,817048,361Jun 12
SANDERS MACHELLEDirectorJun 10 '26Option Exercise0.0038,817046,099Jun 12
Pesicka Edward ADirectorJun 10 '26Option Exercise0.0038,817052,453Jun 12
Morais Mark A.Chief Operating OfficerJun 10 '26Sale16.824,67478,61771,365Jun 12
Ray AmritDirectorJun 10 '26Option Exercise0.0038,817052,453Jun 12
Russell Erin LDirectorJun 10 '26Option Exercise0.0038,817072,617Jun 12
Parks RobertChief Accounting OfficerMay 18 '26Sale13.442,00026,88020,389May 20
NEUPERT PETER MDirectorMay 14 '26Option Exercise0.00148,5360246,668May 18
Russell Erin LDirectorMar 20 '26Option Exercise0.0023,946033,800Mar 24
Morais Mark A.Chief Operating OfficerMar 16 '26Sale9.221,80416,63369,899Mar 17
Mcconnell Jill G.Chief Financial OfficerMar 16 '26Sale9.221,80416,63372,276Mar 17
Morais Mark A.Chief Operating OfficerMar 13 '26Option Exercise0.004,284071,703Mar 17
Mcconnell Jill G.Chief Financial OfficerMar 13 '26Option Exercise0.004,284074,080Mar 17
Mcconnell Jill G.Chief Financial OfficerMar 10 '26Sale9.075,06145,90469,796Mar 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.